1. Immediately upon diagnosis, actively educate on lifestyle modification and self-management methods and monitor whether it is continued. [Randomized controlled trial, general recommendation]

2. Consider the presence of comorbidities (cardiac failure, atherosclerotic cardiovascular disease [ASCVD], and chronic kidney diseases [CKDs]), hypoglycemic effects, effects on weight, risk of hypoglycemia, side effects, treatment acceptability, age, life value pursued by patients, and cost when selecting drugs. [Expert opinion, general recommendation]

3. Initiate insulin therapy for patients with severe hyperglycemia (HbA1c >9.0%) along with hyperglycemic symptoms (polydipsia, polyuria, weight loss, etc.). [Expert opinion, general recommendation]

4. When initiating drug therapy, a monotherapy or combination therapy should be used, taking into consideration the HbA1c goal and current glucose levels. [Randomized controlled trial, general recommendation]

5. Consider combination therapy from the day of diagnosis to reduce the risk of glycemic control failure. [Randomized controlled trial, limited recommendation]

6. Check medication adherence regularly and adjust the medication if necessary. [Expert opinion, general recommendation]

7. If the HbA1c goal is not achieved, the previous drug should be increased in dose or used in combination with a drug of a different class immediately. [Randomized controlled trial, general recommendation]

8. Use metformin first for pharmacotherapy and maintain it unless there are contraindications or side effects. [Randomized controlled trial, general recommendation]

9. When prioritizing a potent glucose-lowering effect, treatment should incorporate injectable therapies. [Randomized controlled trial, general recommendation]

1) When considering combination therapy based on injectables, GLP-1RAs are prioritized over basal insulin. [Randomized controlled trial, general recommendation]

2) If the target blood glucose level is not achieved with either GLP-1RA or basal insulin alone, combine the two drugs. [Randomized controlled trial, limited recommendation]

3) If the target blood glucose level is not achieved using GLP-1RA or basal insulin treatment, initiate intensive insulin therapy. [Randomized controlled trial, limited recommendation]

10. In patients with HF, SGLT2 inhibitors, which have proven benefits in protecting against HF, should be a priority regardless of HbA1c levels and should continue as long as there are no contraindications or adverse reactions. [Randomized controlled trial, general recommendation]

11. If the patients have albuminuria or reduced estimated glomerular filtration rate (eGFR), SGLT2 inhibitors, which have proven benefits in protecting the kidney, should be used as a priority regardless of HbA1c levels and continued as long as there are no contraindications or adverse effects. [Randomized controlled trial, general recommendation]

12. In patients with ASCVD, SGLT2 inhibitors or GLP-1RAs, which have proven cardiovascular benefits, should be prioritized. [Randomized controlled trial, general recommendation]